The Global HIV Injection Market size is expected to reach $2.8 billion by 2030, rising at a market growth of 17.6% CAGR during the forecast period.
North America, particularly the United States, has a relatively high prevalence of HIV compared to other regions. Therefore, the North America segment captured $368.07 million revenue in the market in 2022. This high prevalence creates a substantial demand for HIV medications, including injectable therapies. North America is at the forefront of HIV research and treatment, leading to the development of new and innovative HIV medications, including injectable therapies.
The escalating prevalence of HIV/AIDS necessitates the development of more efficacious treatment modalities to alleviate symptoms and sustain life. This increased demand has driven pharmaceutical companies and researchers to develop new and innovative HIV injections to meet the growing needs of patients. Thus, the increasing prevalence of HIV is supporting the growth of the market.
Additionally, the innovative formulations offer several advantages over traditional oral medications, driving their adoption and increasing demand in the market. Injectable therapies typically require less frequent dosing than oral medications, which can be particularly beneficial for patients with difficulty adhering to complex medication schedules. Therefore, the development of innovative injectable formulations for the treatment of HIV/AIDS has had a positive impact on the demand for HIV injections.
However, the high cost of HIV treatment, including injectable medications, remains a significant barrier to access for many people living with HIV/AIDS, particularly in low- and middle-income countries. The cost of HIV treatment can include not only the price of the medication itself but also the cost of regular monitoring, laboratory tests, and healthcare provider visits, which can quickly add up to a substantial financial burden for patients. Hence, the high cost might hamper the expansion of the market.
The COVID-19 pandemic had a significant impact on the market, affecting various aspects of the supply chain and patient access to treatment. Raw material shortages and manufacturing delays followed disruptions in the global supply chain, which affected HIV medications, including injectable therapies. These disruptions impacted their availability in some regions, potentially leading to treatment interruptions for patients. Thus, the pandemic affected the market negatively
Drivers 
Restraints 
Opportunities 
Challenges Based on distribution channel, the market is divided into hospital pharmacy, drug stores & retail pharmacies, and others. The hospital pharmacy segment procured 46.2% revenue share in the market in 2022. Hospitals, clinics, and other healthcare facilities are major distribution points for HIV injections. They receive medications from pharmaceutical companies or wholesalers and distribute them to patients as part of their treatment regimens.
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The LAMEA segment witnessed 5.3% revenue share in the market in 2022. The LAMEA region has a relatively high prevalence of HIV, with certain countries in sub-Saharan Africa experiencing particularly high rates of infection. Governments in the LAMEA region have implemented various initiatives to address the HIV/AIDS epidemic, including funding for HIV/AIDS programs and improving access to treatment.
Free Valuable Insights: Global HIV Injection Market size to reach USD 2.8 Billion by 2030
| Report Attribute | Details |
|---|---|
| Market size value in 2022 | USD 787.02 Million |
| Market size forecast in 2030 | USD 2.8 Billion |
| Base Year | 2022 |
| Historical Period | 2019 to 2021 |
| Forecast Period | 2023 to 2030 |
| Revenue Growth Rate | CAGR of 17.6% from 2023 to 2030 |
| Number of Pages | 143 |
| Number of Tables | 170 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Distribution Channel, Region |
| Country scope |
|
| Companies Included | GlaxoSmithKline PLC (GSK), Gilead Sciences, Inc., ImmunityBio, Inc., F. Hoffmann-La Roche Ltd., Theratechnologies Inc., Viriom, Inc., AbbVie, Inc., Brii Biosciences Limited, Shionogi & Co., Ltd., Boehringer Ingelheim International GmbH |
By Distribution Channel
By Geography
The Market size is projected to reach USD $2.8 billion by 2030.
Development of innovative injectable formulations are driving the Market in coming years, however, Stigma and discrimination against people living with HIV/AIDS restraints the growth of the Market.
GlaxoSmithKline PLC (GSK), Gilead Sciences, Inc., ImmunityBio, Inc., F. Hoffmann-La Roche Ltd., Theratechnologies Inc., Viriom, Inc., AbbVie, Inc., Brii Biosciences Limited, Shionogi & Co., Ltd., Boehringer Ingelheim International GmbH
The expected CAGR of this Market is 17.6% from 2023 to 2030.
The North America region dominated the Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.3 Billion by 2030.
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
